Skip to main content

Table 2 Overall response rate

From: NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

RESPONSE RATE

RC

2 (4.8 %)

RP

13 (31.7 %)

ORR

15 (36.6 %)

SD

14 (34.2 %)

DCR

26 (70.7)

PD

12 (29.3)

CA19.9 > 50 % reduction

17 (41.5 %)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us